SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 3, 2004
HAEMONETICS CORPORATION
(Exact Name of Registrant as Specified in its Charter)
Massachusetts 1-10730 04-2882273
(State or other jurisdiction of (Commission (IRS Employer
incorporation or organization) File Number) Identification Number)
400 Wood Road
Braintree, MA 02184
(Address of principal executive (Zip Code)
offices)
Registrant's telephone number, including area code (781) 848-7100
Item 9. Regulation FD Disclosure.
-----------------------------------
The following information is intended to be included under "Item 12.
Results of Operations and Financial Condition" and is included under this
Item 9 in accordance with SEC Release No. 33-8216.
On May 3, 2004 Haemonetics Corporation (the "Company") issued a press
release regarding its financial results for the quarter and fiscal year
ended April 3, 2004 and outlook for fiscal 2005. The Company's press
release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and the Exhibit
attached hereto shall not be deemed "filed" for purposes of Section 18 of
the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise
subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933 or
the Exchange Act, regardless of any general incorporation language in such
filing.
Exhibits
--------
99.1 Press Release dated May 3, 2004 of Haemonetics Corporation.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
HAEMONETICS CORPORATION
Date: May 3, 2004 By: s/Ronald J. Ryan
-------------------------------
Ronald J. Ryan, Vice President
and Chief Financial Officer
3